The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Health-care companies fell as traders retreated from some of the highest risk issues.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
It’s been over two years since season 4 hit the streamer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback